Navigation Links
Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab

ing AMD, with additional mechanisms of action as compared with the various anti-VEGF compounds that dominate the market and fill the pipelines of pharmaceutical and biotech companies alike. Given these highly favorable factors, Sphingomab is extremely well positioned in the AMD arena."

Lpath plans to initiate clinical trials for wet AMD in early 2008.

About Lpath

Lpath, Inc., headquartered in San Diego, California, is the category leader in lipidomic-based therapeutics, an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases. Lpath's lead product candidate, Sphingomab, is a monoclonal antibody against a validated cancer target, sphingosine-1-phosphate (S1P), and has demonstrated compelling results in preclinical studies against multiple forms of cancers, against AMD, and against heart failure. Sphingomab is potently anti-angiogenic, yet it has other mechanisms of action that may prove advantageous in the clinical setting. As such, Lpath believes Sphingomab may represent the next generation of anti-angiogenesis-based therapeutics.

Lpath's second product candidate, Lpathomab(TM), is a monoclonal antibody against lysophosphatidic acid (LPA), a key bioactive lipid that has been long recognized as a significant promoter of cancer-cell growth and metastasis in a broad range of tumor types.

Lpath's unique ability to generate antibodies against bioactive lipids is based on its patented ImmuneY2(TM) technology. The company intends to apply the ImmuneY2 process to other important lipid-signaling agents, thereby providing a robust pipeline of antibody-based drug candidates. For more information, visit www.lpath.com

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks an
'"/>




Page: 1 2 3 4

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
9. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
10. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
11. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
Post Your Comments:
(Date:1/23/2015)... 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is ... Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... fiduciary duties to shareholders. On January 21, ... reporting that Advaxis had misrepresented the clinical data for ...
(Date:1/23/2015)... , Jan. 23, 2015  Now available for sale, ... 7,849,611) support that prevents ankle sprains by cushioning the ... it fits securely around the outside of any shoe ... & comfort while still offering protection against sprains. With ...
(Date:1/23/2015)... , Jan. 23, 2015 Cord Blood America, Inc. ( ... or the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, ... today, and provides an update for shareholders detailing why a ... requested. Dear Shareholders, As we reflect ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... CRDC ) today announced that it will release ... 2011, on Monday, February 6, 2012, after the markets close. ... Eastern Time to discuss the financial results and provide an ... Call Details To access the live conference ...
... & Science business of Thomson Reuters announced an ... (IPEA). This partnership provides IPEA,s Direction of Sectorial ... (DISET) branch with access to the Newport ... and tools for sourcing global pharmaceutical ingredients. ...
Cached Medicine Technology:Cardica to Announce Fiscal 2012 Second Quarter Financial Results on Monday, February 6, 2012 2Thomson Reuters Helps Brazil's Institute for Applied Economic Research Identify New Generic Drug Opportunities 2
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Joan Lunden, ... keynote speaker at the upcoming 32nd Annual Miami ... Physicians’ Education Resource®, LLC (PER®) , shares that ... have gone undetected if she had not followed up ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... a famous dress online store for wedding dresses and other ... of wedding dresses , and launches a site-wide women’s dress ... on your big day; the wedding gown is the most ... find the most suitable wedding dress. Now, we are proud ...
Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... Sets New Standard for Prescription Prenatal Vitamins , ... the most comprehensive once-daily prescription prenatal vitamin in its category, ... , ST. LOUIS, Dec. 17 KV ... branded pharmaceutical subsidiary - the U.S. market leader in ...
... Mass., Dec. 17 Biopure Corporation (Nasdaq: ... the Food and Drug Administration (FDA) an investigational new ... 2 clinical trial of the company,s oxygen therapeutic Hemopure(R) ... trial Hemopure would be studied for use ...
... Health Successfully Completed and Closed the Amendment of the ... Governing the November 2006 Notes , ------------------------------------------------- ... Dec. 17 /PRNewswire-FirstCall/ - BELLUS Health Inc. (NASDAQ: ... provided formal notice to the NASDAQ Stock Market of ...
... commit to continue progress. Broadcast video of President Sirleaf,s speech onboard the ... download with registration at www.mercyshipsnews.org or upon request. , ... ... out of the Free Port of Monrovia, Liberia, this past weekend, wrapping ...
... Marketing Pro Toby Younis today announced a free webcast entitled, "BuzzMaking: ... is designed for executives in B2B companies facing challenging revenue goals ... ... December 17, 2008-- Widely recognized B2B marketing expert Toby Younis ...
... America (PHA) is applauding President-elect Barack Obama,s selection of Senator ... and Human Services in his Cabinet. , ... South Dakota, is both known and respected by Physician Hospitals ... , "Tom Daschle is an extraordinary ...
Cached Medicine News:Health News:KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R) 2Health News:KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R) 3Health News:KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R) 4Health News:KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R) 5Health News:Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia 2Health News:Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia 3Health News:BELLUS Health announces formal notice to voluntarily delist from NASDAQ 2Health News:BELLUS Health announces formal notice to voluntarily delist from NASDAQ 3Health News:Mercy Ship Sails On From Liberia After Four-Year Rebuilding Effort 2Health News:Mercy Ship Sails On From Liberia After Four-Year Rebuilding Effort 3Health News:B2B Marketing Pro Toby Younis Announces Free Webcast on "BuzzMaking" 2Health News:Physician Hospitals of America (PHA) Applauds President-Elect Obama's Selection of Sen. Daschle as HHS Secretary 2
... average 5:1 increase in usage time at all ... standard cannula. , ,The combination of the ... patients a superior alternative to liquid oxygen. , ... , ,NOTE: Each model ...
... An All-In-One Conserver., ,Offers an average 5:1 ... ,Allows the use of a standard cannula. ... and lightweight cylinders offers ambulatory oxygen patients a ... backed by a 2-year warranty. ...
... average 5:1 increase in usage time at all ... standard cannula. , ,The combination of the ... patients a superior alternative to liquid oxygen. , ... , ,NOTE: Each model ...
... an average 5:1 increase in usage time at ... a standard cannula. , ,The combination of ... oxygen patients a superior alternative to liquid oxygen. ... , ,NOTE: Each ...
Medicine Products: